You are here

Home » Library » HCV Treatment in 2016: Genotypes 1, 2, and 3

HCV Treatment in 2016: Genotypes 1, 2, and 3

Publish date: October 12, 2016

Note: This is an archived resource. It is provided here for general reference, but users are advised to refer to other sources to confirm information. See full site Disclaimer.

AETC source: Southeast AETC

Objectives

  • List available HCV direct acting antivirals (DAAs) available for HCV therapy in 2016
  • Describe appropriate HCV DAA therapies for HCV genotypes 1, 2, and 3
  • Evaluate the potential for DAA drug-drug interactions, particularly with HIV antiretroviral therapy.

Presented by:

Cody Chastain, MD
Assistant Professor, Viral Hepatitis Program
Vanderbilt University School of Medicine, Division of Infectious Diseases

Browse more

Language: English

Topic(s): Antiretroviral Therapy, Drug Interactions, OIs & Comorbid Conditions, Comorbidities, Coinfections, & Complications, Viral Hepatitis Coinfection

Resource type: Online and Self-Paced Learning

Add comment

Log in to post comments

We'd like your feedback

Check all that apply
Check all that apply
Include your email address if you would like a response
Include your email address if you would like a response